Around 2 to 3 months: symptoms often improve a lot if dose increases have been slow
This is normal and expected
GLP-1 medications could work by improving your bodys response to insulin
Ma Z, Jin K, Yue M, Chen X, Chen J
In the realm of peptide-based weight management, tirzepatide represents a new generation, similar to how smartphones have evolved from flip phones
Furthermore, in January 2025, the FDA approved semaglutide (Ozempic ) for reducing the risk of kidney failure and disease progression in patients with diabetes and chronic kidney disease (CKD), making it the first GLP-1 agent indicated for the treatment of CKD (Perkovic et al., 2024)